摘要
目的 探究孟鲁司特联合盐酸氨溴索对分泌性中耳炎(SOM)患者的临床疗效.方法 收集2021年2月至2023年7月联勤保障部队第九八八医院收治的102例SOM患者作为研究对象,对其病例资料进行回顾性分析,根据治疗方案不同将患者分为对照组(盐酸氨溴索治疗)和联合组(孟鲁司特联合盐酸氨溴索治疗),各51例.比较2组临床疗效、治疗前后鼓室压、纯音气导听阈值、血清相关因子[超敏C反应蛋白(hs-CRP)、白细胞介素-8(IL-8)、高迁移率族蛋白B1(HMGB1)、降钙素原(PCT)]水平和复发率.结果 联合组临床总有效率为98.04％,显著高于对照组的84.31％(P＜0.05);治疗后,联合组鼓室压、纯音气导听阈值、血清hs-CRP、IL-8、HMGB1及PCT水平均显著低于对照组(P＜0.001);联合组复发率2.04％,显著低于对照组的16.33％(P=0.036).结论 孟鲁司特联合盐酸氨溴索治疗SOM疗效显著,可改善患者听力水平,调节炎性因子水平,且复发率低.
Abstract
Objective To investigate the effects of montelukast combined with ambroxol hydrochloride on tympanic pressure and serum high mobility group protein B1(HMGB1)and pro-calcitonin(PCT)levels in patients with secretory otitis media(SOM).Methods A total of 102 SOM patients admitted to our hospital from February 2021 to July 2023 were selected as the stud-y objects.According to different treatment regimens,the patients were divided into control group and combination group,with 51 cases in each group.The control group was treated with ambroxol hydrochloride,and the combined group was treated with montelukast combined with ambroxol hydrochloride.The clinical efficacy,tympanical pressure before and after treatment,pure tone gas conduction threshold,serum related factors[hypersensitive C-reactive protein(hs-CRP),interleu-kin-8(IL-8),HMGB1,PCT]levels and recurrence rate were compared between the two groups.Results The total effective rate of combined group(98.04％)was higher than that of control group(84.31％),the difference was significant(P＜0.05).After treatment,tympanic depression in combination group was significantly lower than that in control group(P＜0.05).After treatment,the pure tone gas conduction threshold of 0.5 kHz,1 kHz and 2 kHz in combination group was lower than that in control group,and the difference was significant(P＜0.05).After treatment,the serum levels of hs-CRP,IL-8,HMGB1 and PCT in combination group were lower than those in control group,and the differences were significant(P＜0.05).The 3-month recurrence rate of the combined group was 2.04％lower than that of the control group(16.33％,P＜0.05).Conclusion Montelukast combined with ambroxol hydrochloride is effective in the treatment of SOM,which can improve hearing,promote the secretion of active substances on the surface of eustachan tube,inhibit inflammation and reduce the recurrence rate.
基金项目
河南省医学科技攻关省部共建重点项目(SBGJ202102207)
NETL
NSTL
万方数据